256 related articles for article (PubMed ID: 36430833)
1. Antiandrogenic Effects of a Polyphenol in
Kudo Y; Endo S; Tanio M; Saka T; Himura R; Abe N; Takeda M; Yamaguchi E; Yoshino Y; Arai Y; Kashiwagi H; Oyama M; Itoh A; Shiota M; Fujimoto N; Ikari A
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430833
[TBL] [Abstract][Full Text] [Related]
2. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
Patki M; Huang Y; Ratnam M
Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
[TBL] [Abstract][Full Text] [Related]
3. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
[TBL] [Abstract][Full Text] [Related]
4. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Chung C; Abboud K
Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
[TBL] [Abstract][Full Text] [Related]
5. Steroidogenesis in castration-resistant prostate cancer.
Shiota M; Endo S; Blas L; Fujimoto N; Eto M
Urol Oncol; 2023 May; 41(5):240-251. PubMed ID: 36376200
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.
Singh KB; Ji X; Singh SV
Mol Cancer Ther; 2018 Oct; 17(10):2079-2090. PubMed ID: 30030299
[TBL] [Abstract][Full Text] [Related]
7. Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.
Chattopadhyay I; Wang J; Qin M; Gao L; Holtz R; Vessella RL; Leach RW; Gelman IH
Oncotarget; 2017 Feb; 8(6):10324-10347. PubMed ID: 28055971
[TBL] [Abstract][Full Text] [Related]
8. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
[TBL] [Abstract][Full Text] [Related]
9. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Dalrymple S; Brennen WN; Isaacs JT; Li D; Lakely B; DeLucia DC; Lee JK; Schweizer MT; Lin DW; Corey E; Nelson PS; Morrissey C
Prostate; 2024 Jan; 84(1):100-110. PubMed ID: 37796107
[TBL] [Abstract][Full Text] [Related]
10. The role of adrenal derived androgens in castration resistant prostate cancer.
Barnard M; Mostaghel EA; Auchus RJ; Storbeck KH
J Steroid Biochem Mol Biol; 2020 Mar; 197():105506. PubMed ID: 31672619
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
12. Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer.
Denmeade SR; Sena LA; Wang H; Antonarakis ES; Markowski MC
Oncologist; 2023 Jun; 28(6):465-473. PubMed ID: 37027449
[TBL] [Abstract][Full Text] [Related]
13. Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer.
Mostaghel EA; Zhang A; Hernandez S; Marck BT; Zhang X; Tamae D; Biehl HE; Tretiakova M; Bartlett J; Burns J; Dumpit R; Ang L; Matsumoto AM; Penning TM; Balk SP; Morrissey C; Corey E; True LD; Nelson PS
Clin Cancer Res; 2019 Jan; 25(1):426-439. PubMed ID: 30181386
[TBL] [Abstract][Full Text] [Related]
14. Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer.
Shin WS; Han SH; Jo KW; Cho Y; Kim KT
Sci Rep; 2023 Oct; 13(1):16663. PubMed ID: 37794090
[TBL] [Abstract][Full Text] [Related]
15. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
16. Ginsenoside compound K suppresses tumour growth in the 22Rv1 xenograft model and inhibits androgenic responses via the transcriptional mechanism in human prostate cancer cells.
Jiang M; Sun Y; Song K
FEBS J; 2023 Apr; 290(7):1840-1854. PubMed ID: 36349420
[TBL] [Abstract][Full Text] [Related]
17. Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression.
Qiao J; Grabowska MM; Forestier-Roman IS; Mirosevich J; Case TC; Chung DH; Cates JM; Matusik RJ; Manning HC; Jin R
Oncotarget; 2016 Sep; 7(38):61955-61969. PubMed ID: 27542219
[TBL] [Abstract][Full Text] [Related]
18. The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor.
Copello VA; Burnstein KL
Oncogene; 2022 May; 41(20):2824-2832. PubMed ID: 35418689
[TBL] [Abstract][Full Text] [Related]
19. A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer.
Dahiya NR; Chandrasekaran B; Kolluru V; Ankem M; Damodaran C; Vadhanam MV
Mol Carcinog; 2018 Oct; 57(10):1332-1341. PubMed ID: 30069922
[TBL] [Abstract][Full Text] [Related]
20. 11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer?
Storbeck KH; Bloem LM; Africander D; Schloms L; Swart P; Swart AC
Mol Cell Endocrinol; 2013 Sep; 377(1-2):135-46. PubMed ID: 23856005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
